National Medical Products Administration: Deepen the reform of the review and approval system, stimulate innovation vitality in the pharmaceutical industry.

On May 25th, Huang Guo, the Secretary of the Party Group and Director of the National Medical Products Administration, chaired a collective study meeting of the Party Group's theoretical learning center. The meeting emphasized the importance of prioritizing standards, strengthening the foundation of drug safety at the source; adhering to strict management and control, and weaving a tight network of supervision throughout the entire process; and cracking down severely on illegal activities in order to empower the high-quality development of the pharmaceutical industry through reform and innovation. The meeting also called for deepening the reform of the drug evaluation and approval system, stimulating the innovation vitality of the pharmaceutical industry; innovating regulatory methods to continuously improve regulatory efficiency; and improving the traditional Chinese medicine scientific supervision system to promote innovation and development in traditional Chinese medicine. It also stressed the importance of perfecting the drug safety responsibility system with a systematic approach, by emphasizing and implementing the responsibilities of enterprises, local authorities, regulatory departments, and societal governance to gather the broadest range of efforts to ensure drug safety.